Psychiatry 2008 - September 2008 - (Page 18)

Psychiatry 2008 [psych Rx] Psychiatry 2008 is a peer-reviewed journal that provides evidence-based information to practicing clinicians—information clinicians can actually apply to their daily practices. We are looking for submissions of original research, practical discussions of the latest research, comprehensive reviews, didactic case reports, and provocative commentaries on contemporary topics in psychiatry. Review Article. Comprehensive articles summarizing basic strategies to facilitate the psychiatrist’s approach to diagnosis and treatment and articles highlighting emerging diagnostic and therapeutic modalities. May also include in-depth reviews of clinical practice, management, reimbursement, educational, ethical, and legal issues. Case Report. Short presentations of actual cases that stimulate research and the exchange of information and illustrate the signs and symptoms, diagnosis, and treatment of a disorder. Original Research. Reports of investigations that address questions about clinical care or expand existing knowledge. Brief Report. Short reports of original studies or evaluations or unique, first-time reports of clinical case series. Special Communication. Communications that describe an important issue in psychiatric medicine in a scholarly, thorough, well-referenced, systematic or evidence-based manner. Commentary. Essays that address important topics in psychiatric medicine and generally are not linked to a specific article. Letter to the Editor. Opinions on cases or articles published in Psychiatry 2008, opinions on other current topics, or short reports of clinical interest. To submit an article or to discuss an article idea, please contact: Elizabeth A. Klumpp, Executive Editor, Phone 610.325.9905 Fax 610.325.9906, eklumpp@matrixmedcom.com women, stop taking them because of their sexual side effects. The complaints are common. More than half the people who take antidepressants develop sexual problems, prior studies have found, especially for people taking Prozac, Paxil, Celexa, and other drugs that work by increasing the chemical serotonin in the brain. Serotonin is thought to slow down orgasm, perhaps by diminishing the release of another brain chemical, dopamine. Viagra increases blood flow to sex organs. Pfizer Inc. spokeswoman Sally Beatty said the company currently has no plans to pursue FDA approval for using its drug Viagra as a treatment for female sexual dysfunction. The company ended its internal research on Viagra for women in 2004. While Viagra was found to be safe, the results were inconclusive, Beatty said in an e-mail. The new Viagra findings are based on an eight-week experiment. The 98 women were using antidepressants successfully but were having sexual problems. Their average age was 37. The women agreed to attempt sexual activity at least once each week. Each time, they took a pill, not knowing whether it was Viagra or a matching dummy pill. While 72 percent of the women taking Viagra reported improvement on an overall scale, only 27 percent of the women taking the placebo reported improvement. Althof said it’s “worrisome” that 43 percent of the women on Viagra experienced headaches, compared with 27 percent of the women on dummy pills. Indigestion and reddening of skin (flushing) also were reported more often by the women taking Viagra. Psychologist Leonore Tiefer of New York University School of Medicine said industry-funded research has oversimplified women’s sexual experience. She noted the new study, funded by a Pfizer grant, found more side effects than benefits. “Where’s the question to the women: Is it worth it?” Tiefer said. An earlier study in men taking antidepressants found more pronounced sexual benefits with Viagra than the benefits found for women, said lead author Dr. George Nurnberg, a psychiatrist at the University of New Mexico School of Medicine in Albuquerque. But the message for men and women who need antidepressants is that Viagra may help them stay on the drugs, he said. “We’re not talking about a lifestyle issue. We’re talking about a medical necessity issue,” Nurnberg said. Pfizer had no influence on the design, findings, or manuscript, Nurnberg said. He and several of the other authors disclosed financial ties to Pfizer and other drugmakers. www.psychiatrymmc.com 18 Psychiatry 2008 [SEPTEMBER] http://www.psychiatrymmc.com

Table of Contents Feed for the Digital Edition of Psychiatry 2008 - September 2008

Psychiatry 2008 - September 2008 Editor’s Message Editorial Advisory Board Contents Psych Rx Letters to the Editor Use of Benzodiazepines in the Treatment of Anxiety Functional Neurosurgery in the Treatment of Severe Obsessive Compulsive Disorder and Major Depression: Overview of Disease Circuits and Therapeutic Targeting for the Clinician Treatment of Comorbid Adolescent Cannabis Use and Major Depressive Disorder Risperidone Long-acting Injections: Successful Alternative Deltoid Muscle Injections for Refractory Schizophrenia Alcohol/Substance Misuse and Treatment Nonadherence: Fatal Attraction Transforming the Psychiatric Inpatient Unit from Short-term Pseudo-asylum Care to State-of-the-art Treatment Setting Journal Watch Classified Advertising Information for Authors

Psychiatry 2008 - September 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.